aducanumab

Biogen submits aducanumab data for FDA review Biogen announced the completion of its regulatory filing to the U.S. Food and Drug Administration (FDA) on aducanumab for the treatment of dementia and mild cognitive impairment due to Alzheimer's. If approved, aducanumab would become the first therapy to reduce the cognitive and functional decline of people living with the disease.